Disclosure of “flat closure” status often carries stigma and vulnerability, underscoring the importance of neutral, affirming ...

Skilled oncology nursing reduced treatment-related distress through procedural coaching, symptom vigilance during ...

Janet Fuller, DNP, RN, OCN, of Vanderbilt University Medical Center, helped two young breast cancer patients form a support group that now guides dozens of women through diagnosis and treatment.

Janet Fuller, DNP, RN, OCN, of Vanderbilt University Medical Center, helped two young breast cancer patients form a support group that now guides dozens of women through diagnosis and treatment. A ...

First-line therapy for HER2-positive, MMR-proficient/MSS gastroesophageal cancer now permits multiple HER2-targeting antibodies with chemotherapy, rather than specifying trastuzumab exclusively.

Andrew Evens, DO & Joanna Rhodes, MD on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering ...

Medicare Part D plans are required to cover all or nearly all cancer drugs. That has not stopped them from denying coverage in individual cases. When patients push back, roughly 1 ...

Extended follow-up demonstrated reduced mortality risk with pTVG-HP plus GM-CSF versus GM-CSF alone (median OS 13.4 vs 8.6 ...

Three years after ringing the bell for lymphoma, the cancer came back in my brain. Choosing hospice care was the hardest ...

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

In the phase 2 SANRECO trial, 88% of patients with polycythemia vera kept hematocrit below 45% without a phlebotomy. Lead investigator Dr. Marina Kremyanskaya explains what that could mean day to day.

Andrew Evens, DO & Joanna Rhodes, MD on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.